Solid Biosciences (NASDAQ:SLDB – Get Free Report) was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a report issued on Monday, Zacks.com reports.
SLDB has been the subject of several other research reports. Piper Sandler reiterated an “overweight” rating and set a $20.00 target price on shares of Solid Biosciences in a research note on Friday, June 21st. Barclays lowered their price target on shares of Solid Biosciences from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, May 16th. William Blair restated an “outperform” rating on shares of Solid Biosciences in a research report on Thursday, March 28th. Citigroup began coverage on shares of Solid Biosciences in a research report on Friday, March 15th. They set a “buy” rating and a $16.00 price target for the company. Finally, SVB Leerink upgraded shares of Solid Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Monday. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $15.33.
Check Out Our Latest Stock Analysis on Solid Biosciences
Solid Biosciences Trading Down 12.4 %
Solid Biosciences (NASDAQ:SLDB – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Equities research analysts predict that Solid Biosciences will post -2.65 EPS for the current fiscal year.
Institutional Investors Weigh In On Solid Biosciences
A number of large investors have recently added to or reduced their stakes in SLDB. Vestal Point Capital LP bought a new stake in shares of Solid Biosciences in the fourth quarter valued at approximately $209,000. Bain Capital Life Sciences Investors LLC boosted its position in shares of Solid Biosciences by 28.9% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 4,034,582 shares of the company’s stock valued at $53,741,000 after acquiring an additional 904,160 shares during the period. RA Capital Management L.P. boosted its position in shares of Solid Biosciences by 26.4% in the first quarter. RA Capital Management L.P. now owns 4,330,446 shares of the company’s stock valued at $57,682,000 after acquiring an additional 904,160 shares during the period. Vanguard Group Inc. lifted its position in Solid Biosciences by 283.9% in the first quarter. Vanguard Group Inc. now owns 1,244,575 shares of the company’s stock worth $16,578,000 after purchasing an additional 920,404 shares during the period. Finally, Artal Group S.A. lifted its position in Solid Biosciences by 175.0% in the first quarter. Artal Group S.A. now owns 2,500,000 shares of the company’s stock worth $33,300,000 after purchasing an additional 1,590,781 shares during the period. Institutional investors own 81.46% of the company’s stock.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Read More
- Five stocks we like better than Solid Biosciences
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- ETF Screener: Uses and Step-by-Step Guide
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.